Key points are not available for this paper at this time.
Tumor-associated macrophages (TAMs) are among the main contributors to immune suppression in the tumor microenvironment, however, TAM depletion strategies have yielded little clinical benefit. Here, we discuss the concept that TAMs are also key regulators of anti-PD(L)-1-mediated CD8 T cell-dependent immunity. Emerging data suggest that expression of the chemokine CXCL9 by TAMs regulates the recruitment and positioning of CXCR3-expressing stem-like CD8 T (Tstem) cells that underlie clinical responses to anti-PD(L)-1 treatment. We evaluate clinical and mechanistic studies that establish relationships between CXCL9-expressing TAMs, Tstem and antitumor immunity. Therapies that enhance anti-PD(L)-1 response rates must consider TAM CXCL9 expression. In this perspective, we discuss opportunities to enhance the frequency and function of CXCL9 expressing TAMs and draw on comparative analyzes from infectious disease models to highlight potential functions of these cells beyond Tstem recruitment.
Building similarity graph...
Analyzing shared references across papers
Loading...
Paola Marcovecchio
Pfizer (United States)
Graham D. Thomas
Pfizer (United States)
Shahram Salek‐Ardakani
Inhibrx (United States)
Journal for ImmunoTherapy of Cancer
SHILAP Revista de lepidopterología
Pfizer (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Marcovecchio et al. (Mon,) studied this question.
synapsesocial.com/papers/69d6ca1d8dca315383ed8f1b — DOI: https://doi.org/10.1136/jitc-2020-002045
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: